Pro-Insulin ELISA 胰岛素原ELISA检测试剂盒

产品描述

Category Name： Steroids

Method： ELISA

Principle： ELISA

Controls Standards： 0,2.6,6.6,16.5,33,66pmol/l

Sensitivity： 1pmol/l

Sample： 100 µl

Runtime：

Wavelength： 450 nm

Safety： Please refer to MSDS

Shelflife： 18 Months

INTENDED USE

The Calbiotech Pro-Insulin ELISA Kit is intended for the quantitative measurement of insulinomas in human serum or plasma.

SUMMARY AND EXPLANATION

Proinsulin is a 9390 MW polypeptide of 86 amino acids, that is synthesized in the ß cells of the pancreas and is the precursor molecule for insulin. Most proinsulin is converted to insulin and C-Peptide, which are secreted in equimolar amounts into the blood. About 15 % is not converted and is released as proinsulin. The biological activity of proinsulin is only about 10% of Insulin, but the half life of proinsulin is three times as long as insulin. The level of proinsulin in serum can be a reflection of ß cell status. Both IDDM and NIDDM are characterized by dysfunction of the pancreatic ß cells. Elevated proinsulin levels have been noted at the onset of IDDM and in healthy siblings of IDDM patients. Proinsulin levels may also be increased in patients with established NIDDM. Increased levels of circulating proinsulin are found in older patients, pregnant or obese diabetics, patients with insulinomas, functional hypoglycemia and hyperinsulinemia, a rare syndrome. Because the structure of proinsulin is similar to insulin, proinsulin may be detected as immunoreactive insulin in the insulin assay. Immunoreactive insulin levels are generally determined in conventional RIA's, which overestimate the insulin level because the methods use antibodies which crossreact with proinsulin. By calculating the molar ration of proinsulin to true insulin (P/I), a better assessment of ß cell function can be made.

PRINCIPLE OF THE TEST

The Calbiotech Inc. Proinsulin EIA is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. The microtiter wells are coated with a monoclonal antibody directed towards a unique antigenic site on a Proinsulin molecule. An aliquot of patient sample containing endogenous Proinsulin is incubated in the coated wells. After washing off the samples in a second step an enzyme conjugate, which is an anti-Proinsulin antibody conjugated with horseradish peroxidase is incubated in the wells. After incubation the unbound conjugate is washed off with wash solution. Having added the substrate solution, the intensity of colour developed is proportional to the concentration of Proinsulin in the patient sample.